Sonelokimab for psoriatic arthritis: Results from the phase II ARGO trial

The phase II ARGO trial (NCT05640245) is assessing the safety and efficacy of sonelokimab, a dual-inhibitor of interleukin (IL)-17A and IL-17F, in patients with active psoriatic arthritis.¹ Topline results from this trial were reported previously by the Psoriasis and Psoriatic Arthritis Hub. Week 12 results from this trial were presented at the European Alliance of Associations for Rheumatology (EULAR) 2024 Congress by McInnes.¹

The primary endpoint was met; at Week 12, a greater proportion of patients treated with either sonelokimab 60 mg (n = 41) or 120 mg (n = 43) with induction achieved a 50% improvement in American College of Rheumatology score (ACR50) vs placebo (46.3% and 46.5% vs 20.0%; p < 0.05 and p < 0.01, respectively).

Additionally, at Week 12, more patients treated with sonelokimab achieved an ACR20 and Psoriasis Area and Severity Index 90 response vs placebo; this onset of response was rapid, with improvements observed by Week 4.

Sonelokimab was well tolerated, with no new safety signals.